May 27, 2024

DNA Synthesizer Market With Analysis Of New Business Opportunities After Covid-19 Impact

The DNA Synthesizer Market is estimated to be valued at US$ 4.3 Bn in 2023 and is expected to exhibit a CAGR of 20.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

DNA synthesizers are laboratory instruments used for chemical synthesis of DNA fragments, specifically in the field of molecular biology and genetic engineering. These instruments use solid-phase synthesis techniques for the stepwise incorporation of nucleotides into oligonucleotides. DNA synthesizers offer automated synthesis of single-stranded DNA fragments up to 200 nucleotides in length at commercial scale. They are commonly used by researchers for processes such as site-directed mutagenesis, oligonucleotide hybridization, and generating probes.

Market Dynamics:

The growth of the DNA synthesizer market is driven by increasing R&D funding for molecular biology research and advancements in DNA sequencing techniques. According to the Coalition for Heath Funding report, the United States federal investment on biomedical, behavioral, and social sciences research in 2021 was US$ 42 Bn. Further, burgeoning demand for genomics and DNA sequencing from pharmaceutical and biotechnology companies is also fueling market growth. For instance, according to Eurofins Genomics reports, the demand for DNA sequencing has increased 15-20% annually in recent years.

Read More @ https://www.coherentmarketinsights.com/market-insight/dna-synthesizer-market-5913

Additionally, the introduction of cloud platforms by manufacturers for remote access and management of DNA synthesizers is expected to positively impact market revenues over the forecast period. Cloud platforms enable researchers to operate synthesizers from any location while making instrument usage data available in real-time. This will allow improved synthesis workflow management and reduce device down-time. Cloud-based infrastructure also reduces upfront investment costs associated with DNA synthesis and expands market reach.

Segment Analysis

The DNA synthesizer market is dominated by instruments segment. This segment accounts for over 60% of the overall market share as of 2023. DNA synthesizers find widespread application in DNA amplification, gene editing and genetic engineering, which requires instruments for DNA fragment assembly and amplification. Advances in DNA sequencing technologies and growing applications of synthesized DNA in genomics, proteomics and forensics is driving the demand for DNA synthesizer instruments.

PEST Analysis

Political: Government funding for genomic research and investments in developing synthetic biology innovations will support the growth of DNA synthesizer market. Economic: Growing biotechnology and pharmaceutical industries coupled with rising R&D spending on drug discovery and precision medicine is fueling the demand for DNA synthesizers. Social: Rising incidence of genetic diseases and cancers is creating awareness about personalized medicine and driving need for biomarkers and diagnostics developed using synthesized DNA. Technological: Advancements in DNA sequencing, genome editing technologies and lab automation solutions is enhancing capabilities of DNA synthesizers, improving efficiency, throughput and lowering costs.

Key Takeaways

The global DNA Synthesizer Market is expected to witness high growth, exhibiting 20% CAGR over the forecast period, due to increasing investments in genomics and synthetic biology research.

Regional analysis: North America dominated the global DNA synthesizer market in 2023, accounting for over 40% share owing to presence of leading biopharma companies and large genomics research funding in the US. Asia Pacific is expected to be the fastest growing region during the forecast period supported by increasing R&D expenditures in countries like China and India.

Key players operating in the DNA synthesizer market are Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Danaher Corporation , GenScript Biotech Corporation, Eurofins Genomics, LGC Limited, BioAutomation Corporation, Bio-Rad Laboratories, Twist Bioscience Corporation, Hamilton Company, New England Biolabs, Nippon Genetics, LGC Biosearch Technologies, DNA Script, Ribbon Biolabs GmbH, and Camena Bioscience.